Health Care Utilization in the 6 Months Following SARS-CoV-2 Infection
Sara Y. Tartof(Kaiser Permanente), Lei Qian(Kaiser Permanente), Matthew F. Daley(Kaiser Permanente), Ousseny Zerbo(Kaiser Permanente), David L. McClure(Marshfield Clinic), Sharon Saydah(Centers for Disease Control and Prevention), Lina S. Sy(Kaiser Permanente), Jennifer C. Nelson(Kaiser Permanente Washington Health Research Institute), In‐Lu Amy Liu(Kaiser Permanente), Candace C. Fuller(Harvard University), Deborah E. Malden(Morpho (United States)), Eric Weintraub, Michelle L. Henninger(Kaiser Permanente Center for Health Research), Jonathan D. Alpern(University of Minnesota), Joshua T.B. Williams(Denver Health Medical Center), Simon J. Hambidge, Bruno Lewin(Kaiser Permanente)
Cited by 104
Related Papers
Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study
|The Lancet|2021|1.3k
The health status of adults on the autism spectrum
|Autism|2015|1.1k
Effects of the COVID-19 Pandemic on Routine Pediatric Vaccine Ordering and Administration — United States, 2020
|MMWR Morbidity and Mortality Weekly Report|2020|720
Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory Committee on Immunization Practices — United States, June 2021
|MMWR Morbidity and Mortality Weekly Report|2021|602